

University of Strathclyde

Institute of Pharmacy and Biomedical Sciences

The Institute is committed to achieving lasting culture change to benefit its staff, students, industry and the people of Glasgow. We are building closer links with industry, the NHS and policy makers and are currently creating a cross-disciplinary initiative in health technology – Strathclyde Health.

“New medicines, better medicines and better use of medicines” – the core theme for research excellence and impact within the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS).

The Institute has achieved true and lasting culture change across the breadth of research and throughout its community of staff, researchers and students. There is increased awareness of how to maximise impact for the benefit of students and staff, the NHS, the pharmaceutical industry and the people of Glasgow, the UK and globally.

Delivering Impact

Strathclyde’s commitment to sustaining excellence with impact is evidenced by its seeking and investing in a European funding package (£1.067M) to build on activities generated during the Excellence with Impact competition and its appointment of a team embedded within SIPBS dedicated to maximising impact (KE Hub).

The Hub will conduct regular impact audits that capture the current and planned activities of approximately 80 academic staff and the information will be incorporated in the University’s new data management system (Pure).

The Hub has two key components for delivering increased impact and culture change:

- feasibility study funding for establishing and growing relationships between SIPBS and Scottish SMEs
- Project Champions – postdoctoral researchers and postgraduates who take responsibility for driving forward the impact generating aspects of SIPBS technologies. Project Champions have access to impact training via Strathclyde’s world-renowned MBA programme.

The University operates a ‘KT escalator’, supporting industrial interactions within the EPSRC remit and we plan to explore an equivalent model with BBSRC and MRC. The University also has an initiative - Strathclyde Health - involving researchers across four faculties and providing closer links with industry, the NHS and policymakers.

Furthermore, the University has just unveiled plans for a £90M Technology & Innovation Centre that will transform the way universities, business and industry collaborate and become the cornerstone of Scottish Enterprise’s new International Technology and Renewable Energy Zone (ITREZ).




SIPBS – a pioneering, world-class centre for teaching, research & knowledge exchange, with particular focus on drug discovery & development, housed in a £36m purpose-built building

New drug technologies

A late preclinical stage biopharmaceutical company commenced operations in Glasgow to develop and commercialise a new class of antibacterial drug technology that was licensed from Strathclyde.

The company, MGB BioPharma, received start-up funding from an angel syndicate led by Archangel Informal Investments in association with TRI Cap, Barwell and the Scottish Co-Investment fund.

The technology has so far demonstrated very significant *in vitro* and *in vivo* activity against bacteria, including MRSA. MGB BioPharma hopes to licence their novel technology for treatment of serious hospital and community acquired infections – an area of high unmet need.



Bacteria on culture plate: Antibacterial technology licenced from Strathclyde is being used to develop new ways of treating infections such as MRSA

Commercialisation

Fixed Phage is a spin-out company formed to commercialise a technology invented and patented by Strathclyde.

The technology immobilises bacteriophages (viruses that infect and destroy bacteria) onto wound dressings and wound care products to help to prevent MRSA infection. Pre-clinical trials have already been undertaken on a prototype and results have been excellent.

The technology also has applications in human and veterinary medicine, food, agriculture, horticulture, decontamination and packaging. Over the next 18 months, Fixed Phage aims to work with targeted companies to develop and test additional products.



Researchers from Strathclyde have spun out Fixed Phage. The company will develop commercial antibacterial products that use bacteriophages.

Contact

Dr Catherine Breslin
Research & Knowledge Exchange Manager
Research & Knowledge Exchange Services
University of Strathclyde
50 George Street
Glasgow
G1 1QE



Website: www.strath.ac.uk
Email: catherine.breslin@strath.ac.uk
Tel: +44 (0)141 548 3904

BBSRC
**EXCELLENCE
WITH IMPACT**
2011



The BBSRC Excellence with Impact 2011 scheme ran from 2008 to 2010. It was developed to reward and esteem those university departments most active in embedding a culture that recognises and values the achievement of impact alongside excellent research.